Meeting
2021 ASCO Annual Meeting
Inductive camrelizumab and apatinib for patients with locally advanced and resectable oral squamous cell carcinoma: A single-arm trial (Icemelting trial).
Authors
Lai-Ping Zhong
Department of Oral & Maxillofacial-Head & Neck Oncology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Lai-Ping Zhong , Wu-tong Ju , Rong-hui Xia , Qi Zhu , Guopei Zhu , Shengjin Dou , Jiang Li , Min-jun Dong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT04393506
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6052)
DOI
10.1200/JCO.2021.39.15_suppl.6052
Abstract #
6052
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Camrelizumab plus apatinib as induction therapy for locally advanced head and neck squamous cell carcinoma (IMplus): A single-arm phase II study.
First Author: Lulu Ye
Poster
2019 ASCO Annual Meeting
Phase 2 study of camrelizumab (anti-PD-1 antibody) combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma.
First Author: Bo Zhang
Poster
2024 ASCO Annual Meeting
Apatinib and camrelizumab plus hepatic arterial infusion with oxaliplatin and 5-fluorouracil vs. apatinib and camrelizumab as the first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A randomized multi-center clinical trial.
First Author: MinKe He
Poster
2023 ASCO Annual Meeting
A multicenter phase I/II trial of induction chemotherapy followed by camrelizumab, apatinib, plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer.
First Author: Chengzhi Zhou